Back to results
US 11,992,478 B2Granted
Methods of using androgen receptor inhibitors as cancer therapeutics
AssigneeThe Trustees of the University of Pennsylvania
InventorsTodd Ridky, Christopher Natale, Cristina Aguirre Portoles
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating cancer in a subject with a ZIP9 inhibitor. In certain embodiments, the cancerous tissues do not express the nuclear androgen receptor (AR). These methods, alone or in combination with other cancer therapies, can improve treatment outcomes in patients suffering from cancer, particularly male patients.
Claims25
A method of treating or ameliorating cancer, the method comprising:
- administering to a subject in need thereof a composition comprising a therapeutically effective amount of at least one active agent that inhibits ZIP9,
- wherein the at least one active agent is bicalutamide, enzalutamide, flutamide, nilutamide, apalutamide (ARN-509), darolutamide (ODM-201), ralaniten (EPI-001), or dimethylcurcumin (ASC-J9);
- wherein the cancer is selected from the group consisting of squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, renal cell carcinomas, pancreatic cancer, liver cancer, colon cancer, bladder cancer, bowel cancer, kidney cancer, lung cancer, head and neck cancer, stomach cancer, leukemias, benign or malignant lymphomas, benign or malignant melanomas, myeloproliferative diseases, sarcomas, thyroid cancer, astrocytoma, esophageal cancer, carcinosarcoma, Hodgkin's disease, Wilms' tumor, and teratocarcinomas;
- and
- wherein cancerous cells in the cancer do not have detectable levels of androgen receptor (AR) as measured by immunohistochemistry relative to a known AR-expressing and AR-responsive tumor.
2 more elements
A method of treating or ameliorating cancer, the method comprising:
- identifying a subject suffering from cancer that has failed at least one prior cancer therapy, wherein cancerous cells in the cancer do not have detectable levels of androgen receptor (AR) as measured by immunohistochemistry relative to a known AR-expressing and AR-responsive tumor;
- wherein the cancer is selected from the group consisting of squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, renal cell carcinomas, pancreatic cancer, liver cancer, colon cancer, bladder cancer, bowel cancer, kidney cancer, lung cancer, head and neck cancer, stomach cancer, leukemias, benign or malignant lymphomas, benign or malignant melanomas, myeloproliferative diseases, sarcomas, thyroid cancer, astrocytoma, esophageal cancer, carcinosarcoma, Hodgkin's disease, Wilms' tumor, and teratocarcinomas;
- and
- administering to the subject a composition comprising a therapeutically effective amount of at least one active agent that inhibits ZIP9, wherein the at least one active agent is bicalutamide, enzalutamide, flutamide, nilutamide, apalutamide (ARN-509), darolutamide (ODM-201), ralaniten (EPI-001), or dimethylcurcumin (ASC-J9).
1 more element
A method of reducing proliferation of cells in a cancerous tumor, the method comprising:
- contacting cells in the cancerous tumor with at least one active agent that inhibits ZIP9, wherein the at least one active agent is bicalutamide, enzalutamide, flutamide, nilutamide, apalutamide (ARN-509), darolutamide (ODM-201), ralaniten (EPI-001), or dimethylcurcumin (ASC-J9);
- and
- reducing the proliferation of cells in the cancerous tumor,
- wherein the cells in the cancerous tumor do not have detectable levels of androgen receptor (AR) as measured by immunohistochemistry relative to a known AR expressing and AR responsive tumor;
- and
- wherein the cancer is selected from the group consisting of squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, renal cell carcinomas, pancreatic cancer, liver cancer, colon cancer, bladder cancer, bowel cancer, kidney cancer, lung cancer, head and neck cancer, stomach cancer, leukemias, benign or malignant lymphomas, benign or malignant melanomas, myeloproliferative diseases, sarcomas, thyroid cancer, astrocytoma, esophageal cancer, carcinosarcoma, Hodgkin's disease, Wilms' tumor, and teratocarcinomas.
3 more elements
A method of treating or ameliorating cancer, the method comprising:
- administering to a subject in need thereof a composition comprising a therapeutically effective amount of at least one active agent that inhibits ZIP9, wherein the at least one active agent is bicalutamide, enzalutamide, flutamide, nilutamide, apalutamide (ARN-509), darolutamide (ODM-201), ralaniten (EPI-001), or dimethylcurcumin (ASC-J9),
- wherein cells in the cancer do not have detectable levels of androgen receptor (AR) as measured by immunohistochemistry relative to a known AR expressing and AR responsive tumor;
- and
- wherein the cancer is selected from the group consisting of squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, renal cell carcinomas, pancreatic cancer, liver cancer, colon cancer, bladder cancer, bowel cancer, kidney cancer, lung cancer, head and neck cancer, stomach cancer, leukemias, benign or malignant lymphomas, benign or malignant melanomas, myeloproliferative diseases, sarcomas, thyroid cancer, astrocytoma, esophageal cancer, carcinosarcoma, Hodgkin's disease, Wilms' tumor, and teratocarcinomas.
1 more element
Dependencies are inferred from the claim text.